JPM Highlights | WuXi Biologics CEO Dr. Chris Chen: Scaled CRDMO Platform Delivering Sustainable High Growth
PR Newswire —
Total of 945 integrated projects in 2025, including 74 Phase III clinical projects and 25 commercial manufacturing projects 209 new integrated projects in 2025 set a new record, with approximately 50% originating from U.S. clients Complex modalities are WuXi Biologics' core growth engine,...